- Home
- ALXO vs GCDT Comparison
ALXO vs GCDT Comparison
Compare ALXO & GCDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALXO | GCDT |
|---|---|---|
| Founded | 2015 | 1992 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.3M | 57.1M |
| IPO Year | 2020 | 2026 |
Fundamental Metrics
Financial Performance| Metric | ALXO | GCDT |
|---|---|---|
| Price | $1.86 | $4.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $3.30 | N/A |
| AVG Volume (30 Days) | 353.0K | ★ 353.1K |
| Earning Date | 03-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,130,401.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 216.53 |
| 52 Week Low | $0.40 | $4.00 |
| 52 Week High | $2.27 | $5.85 |
Technical Indicators
Market Signals| Indicator | ALXO | GCDT |
|---|---|---|
| Relative Strength Index (RSI) | 67.86 | 37.06 |
| Support Level | $1.36 | $4.00 |
| Resistance Level | $1.93 | $4.65 |
| Average True Range (ATR) | 0.18 | 0.46 |
| MACD | 0.06 | -0.08 |
| Stochastic Oscillator | 88.69 | 15.13 |
Price Performance
Historical ComparisonAbout ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.